Abstract
Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.As many established atypical antipsychotics lose patent exclusivity, use of generic atypical antipsychotics will expectably rise in light of cost. US Food and Drug Administration (FDA) approval of generic drugs requires demonstration of bioequivalence of a generic agent (specifically, a plasma C and area under the curve falling within a 90% confidence interval of 80%-125% of that achieved with a branded formulation) but no required evaluation of efficacy or tolerability. Limited data make it difficult for clinicians to advise patients on when less-expensive generic formulations differ from branded drugs in efficacy or adverse effects.J Clin Psychiatry 2012; 73(4): 497© 2012 Physicians Postgraduate Press, Inc.†‹
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
